Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer.
Caroline Emilie B ThomsenTorben F HansenRikke F AndersenJan LindebjergLars H JensenAnders JakobsenPublished in: Therapeutic advances in medical oncology (2020)
Early therapeutic reconsideration is of utmost importance. A low level of meth-ctDNA after one cycle of chemotherapy in the first line setting is a potential marker for excellent clinical outcomes. The clinical utility should be confirmed in randomized clinical trials.